Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 1, 1996, Pages 75-88

  Wakelkamp, Monique ^a   Alván, Gunnar ^b   Gabrielsson, Johan ^b   Paintaud, Gilles ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; FUROSEMIDE; RENIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIURESIS; DRUG TOLERANCE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MODEL; NATRIURESIS; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

EID: 0029758870     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90170-8     Document Type: Article

References (29)

1. Holford NHG. Parametric models of the time course of drug action. In: van Boxtel CJ, Holford NHG, Danhof M, editors. The in vivo study of drug action. Amsterdam: Elsevier, 1992:61-70.
2. Odlind B, Beermann B. Renal tubular secretion and effects of furosemide. Clin Pharmacol Ther 1980;27: 784-90.
3. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993;21:457-78.
4. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: Concepts and applications. 1st ed. Stockholm: Swedish Pharmaceutical Press, 1994:485-95,631-6.
5. Kaojarern S, Day B, Brater DC. The time course of delivery of furosemide into urine: an independent determinant of overall response. Kidney Int 1982;22: 69-74.
6. Brater DC. Pharmacodynamic considerations in the use of diuretics. Annu Rev Pharmacol Toxicol 1983; 23:45-62.
7. Brater DC. Resistance to loop diuretics: why it happens and what to do about it. Drugs 1985;30: 427-43.
8. Chaturvedi PR, O'Donnell JP, Nicholas JM, Shoenthal DR, Waters DH, Gwilt PR. Steady state absorption kinetics and pharmacodynamics of furosemide in congestive heart failure. Int J Clin Pharmacol Ther Toxicol 1987;25:123-8.
9. Hammarlund MM, Odlind B, Paalzow LK. Acute tolerance to furosemide diuresis in humans: pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1985;233:447-53.
10. Sjöström PA, Odlind BG, Beermann BA, Hammarlund-Udenaes M. On the mechanism of acute tolerance to furosemide diuresis. Scand J Urol Nephrol 1988;22: 133-40.
11. Sjöström PA, Beermann BA, Odlind BG. Delayed tolerance to furosemide diuresis: influence of angiotensin converting enzyme inhibition by lisinopril. Scand J Urol Nephrol 1988;22:317-25.
12. Lindström B. Determination of furosemide concentrations in plasma and urine using high-speed liquid chromatography. J Chromatogr 1974;100:189-91.
13. Berglund H, Boukter S, Theodorsson E, Vallin H, Edhag O. Raised plasma concentrations of atrial natriuretic peptide are independent of left atrial dimensions in patients with chronic atrial fibrillation. Br Heart J 1990;64:9-13.
14. Alván G, Helleday L, Lindholm A, Sanz E, Villén T. Diuretic effect and diuretic efficiency after intravenous dosage of frusemide. Br J Clin Pharmacol 1990; 29:215-9.
15. Alván G, Paintaud G, Eckernäs SA, Grahnén A. Discrepancy between bioavailability as estimated from urinary recovery of frusemide and total diuretic effect. Br J Clin Pharmacol 1992;34:47-52.
16. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994;56:406-19.
17. Greger R, Wangemann P. Loop diuretics. Ren Physiol 1987;10:174-83.
18. Sheiner LB, Verotta D. Further notes on physiologic indirect response models. Clin Pharmacol Ther 1995; 58:238-40.
19. Zhu JB, Koizumi T. The diuretic effect of furosemide in relation to its disposition in man. J Pharmacobiodyn 1987;10:377-83.
20. Hammarlund-Udenaes M, Benet LZ. Furosemide pharmacokinetics and pharmacodynamics in health and disease - an update. J Pharmacokinet Biopharm 1989;17:1-46.
21. Brater DC. Diuretic pharmacokinetics and pharmacodynamics. In: van Boxtel CJ, Holford NHG, Danhof M, editors. The in vivo study of drug action. Amsterdam: Elsevier, 1992:253-75.
22. van Meyel JJM, Smits P, Russel FGM, Gerlag PGG, Tan Y, Gribnau FWJ. Diuretic efficiency of furosemide during continuous administration versus bolus injection in healthy volunteers. Clin Pharmacol Ther 1992;51:440-4.
23. Li T, Lee MG, Chiou WL. Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide. J Pharmacokinet Biopharm 1986;14:495-509.
24. Cogan MG. Renal effects of atrial natriuretic factor. Annu Rev Physiol 1990;52:699-708.
25. Tan ACITL, Russel FGM, Thien T, Benraad TJ. Atrial natriuretic peptide: an overview of clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 1993;24:28-45.
26. + cotransport. Pflugers Arch 1989;414:286-90.
27. Kelly RA, Wilcox CS, Mitch WE, Meyer TW, Souney PF, Rayment CM, et al. Response of the kidney to furosemide; II: effect of captopril on sodium balance. Kidney Int 1983;24:233-9.
28. +, and BP homeostasis in man during furosemide: effects of prazosin and captopril. Kidney Int 1987;31:135-41.
29. de Wardener HE. Idiopathic edema: role of diuretic abuse. Kidney Int 1981;19:881-92.